HPN217 is a BCMA-targeting tri-specific t-cell activating construct (TriTAC) in development for patients with multiple myeloma.

SparkCures ID 367
Developed By Harpoon Therapeutics
Generic Name HPN217
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)